

76. (Amended). The test kit of claim 75, wherein the polypeptide is attached to a solid phase.

80. (Amended). A method for producing antibodies which specifically bind to BS322 antigen, comprising:

administering to an individual an isolated immunogenic polypeptide in an amount sufficient to elicit an immune response,

wherein said immunogenic polypeptide is selected from the group consisting of: SEQ ID NO: 24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, and SEQ ID NO:28.

REMARKS

Reconsideration of the above-identified application in view of the following remarks is respectfully requested.

Drawings

The Examiner requested that Applicants respond to the objections to the Drawings set forth in PTO-948. Applicants mailed corrected drawings in the above-identified application on July 23, 2002.

Rejection of Claims 52-61, 70 and 77-81 Under 35 U.S.C. Sections 101 and 112, First Paragraph

Claims 52-61, 70 and 77-81 are rejected under 35 U.S.C. Sections 101 and 112, first paragraph, for the reasons contained in the previous Office Action.

BS322 is a transcription factor in breast tissue. As discussed in Applicants last Amendment, an alignment between BS322 and NY-BR-1 was provided along with a publication in *Cancer Research* (Jager, D., et al., *Cancer Research*, 61:2055-2061 (2001)). The publication in *Cancer Research* showed that NY-BR-1 is expressed in breast cancer tissues. Applicants argued that since BS322 and NY-BR-1 are the same

molecule that BS322 clearly possessed utility as a diagnostic tool for the detection of breast cancer.

In the present Office Action, the Examiner raised a number of questions regarding the sequence alignment between NY-BR-1 and BS322 provided in Applicants last Amendment. Specifically, the Examiner stated that the sequence alignment between NY-BR-1 and BS322 did not indicate what corresponding sequence of BS322 was actually used to produce the alignment. The Examiner also questioned the difference in length between NY-BR-1 and BS322 and the percentage identity over the entire length of the sequences. Applicants herewith enclose the declaration of Dr. Edward Granados. Applicants submit that this declaration answers many of the questions raised by the Examiner in the Office Action.

The Examiner also states that Applicants have not provided a comparison of the polypeptide sequences of SEQ ID NOS:25-28 with the polypeptide sequence of NY-BR-1. Applicants submit that this issue has also been addressed in the declaration of Dr. Granados. As the Examiner is already aware, SEQ ID NO:9 is the consensus sequence for BS322. It contains 3 open reading frames. As shown by the alignments provided, BS322 and N4-BR-1 are highly related sequences and therefore would have similar utility to detect breast cancer.

Thereupon, in view of the Declaration of Dr. Granados and the arguments provided in Applicants previous Amendment, Applicants submit that this rejection should be withdrawn.

Rejection of Claims 52-61 Under 35 U.S.C. Section 112, First Paragraph

Claims 52-61 are rejected under 35 U.S.C. Section 112, First Paragraph as containing subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the art that the inventor, at the time the application was filed, had possession of the claimed invention.

In view of the amendments to claims 52, 55, 57, 60 and 61 to remove the percent homology language, Applicants submit that this rejection has now been rendered moot and should be withdrawn.

Rejection of claims 62-69, 72-76 and 80 Under 35 U.S.C. Section 112, Second Paragraph as being indefinite.

Claims 62-69, 72-76 and 80 are rejected under 35 U.S.C. Section 112, Second Paragraph as being indefinite.

Applicants have amended claims to clarify that the isolated polypeptides according to SEQ ID NO:24-28 are not isolated polynucleotides or DNA molecules. Applicants thank the Examiner for pointing out this discrepancy. In view of the aforementioned arguments, Applicants submit that this rejection should be withdrawn.

CONCLUSION

In view of the aforementioned amendments and arguments, Applicants submit that the above-identified claims are now in condition for allowance.



23492

ABBOTT LABORATORIES
Telephone: (847) 935-7550
Facsimile: (847) 938-2623

Wood, Phillips, Katz, Mortimer & Clark
500 West Madison Street
Suite 3800
Chicago, IL 60662-2511
Phone: (312) 876-2109
Fax: (312) 876-2020

Respectfully submitted,
P.A. Billing-Medel, et al.

Mimi C. Goller
Registration No. 39,046
Attorney for Applicants

Lisa V. Mueller
Registration No. 38,978
Attorney for Applicants

Version with Markings to Show Changes Made

52. (Twice Amended). A purified polypeptide[, having at least 95% identity over the entire length of a] having an amino acid sequence selected from the group consisting of: SEQ ID NO: 24, SEQ[UENCE] ID NO:25, SEQ[UENCE] ID NO:26, SEQ[UENCE] ID NO:27, and SEQ[UENCE] ID NO:28.

55. (Twice Amended). A test kit for determining if a BS322 antigen or anti-BS322 antibody is present in a test sample, said kit comprising:

a container containing at least one BS322 polypeptide having [at least 95% identity over the entire length of] a sequence selected from the group consisting of SEQ ID NO: 24, SEQ[UENCE] ID NO:25, SEQ[UENCE] ID NO:26, SEQ[UENCE] ID NO:27, [and] SEQ[UENCE] ID NO:28.

57. (Amended). A method for detecting at least one antibody specific for a BS322 antigen in a test sample suspect of containing the antibody, said method comprising:

(a) contacting the test sample with a BS322 polypeptide for a time and under conditions sufficient to allow antigen/antibody complexes to form;

wherein said BS322 polypeptide contains at least one BS322 epitope derived from an amino acid sequence [having at least 90% identity over the entire length of a sequence] selected from the group consisting of SEQ ID NO[S]:24[28] SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, and SEQ ID NO: 28 and

(b) detecting the presence of said complexes as an indication of the antibody specific for the BS322 antigen.

60. (Amended). A method for producing antibodies which specifically bind to a BS322 antigen, said method comprising:

administering to an individual an isolated immunogenic polypeptide in an amount sufficient to elicit an immune response,

wherein said immunogenic polypeptide comprises at least one BS322 epitope and has [at least 90% identity over the entire length of] a sequence selected from the group consisting of: SEQ ID NO[S]:24[-28] SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, and SEQ ID NO: 28.

61. (Amended). A method for producing antibodies which specifically bind to a BS322 antigen, comprising:

administering to an individual a plasmid,

wherein said plasmid comprises a sequence which encodes at least one BS322 epitope derived from a polypeptide having an amino acid sequence [with least 90% identity over the entire length of a sequence] selected from the group consisting of SEQ ID NO[S]:24[-28] SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, and SEQ ID NO: 28.

62. (Amended). A purified [polynucleotide] polypeptide, selected from the group consisting of: SEQ ID NO:24, SEQ ID NO[S]:25[-28], SEQ ID NO: 26, SEQ ID NO: 27, and SEQ ID NO: 28.

63. (Amended). The [polynucleotide] polypeptide of claim 62, wherein said [polynucleotide] polypeptide is produced by recombinant techniques.

64. (Amended). The [polynucleotide] polypeptide of claim 62, wherein said [polynucleotide] polypeptide is produced by synthetic techniques.

65. (Amended). A test kit for determining if BS322 antigen or anti-BS322 antibody is present in a test sample, said kit comprising:

a container containing at least one purified [polynucleotide] polypeptide selected from the group consisting of SEQ ID NO[S]:24[-28] SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, and SEQ ID NO: 28.

66. (Amended). The test kit of claim 65, wherein the purified [polynucleotide] polypeptide is attached to a solid phase.

67. (Amended). A method for detecting at least one antibody specific for a BS322 antigen in a test sample suspected of containing the antibody, said method comprising:

(a) contacting the test sample with a [polynucleotide] polypeptide for a time and under conditions sufficient to allow antigen/antibody complexes to form;

wherein the [polynucleotide] polypeptide contains at least one epitope derived from a sequence selected from the group consisting of: SEQ ID NO[S]:24[-28 and degenerate codon equivalents thereof] SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, and SEQ ID NO: 28; and

(b) detecting the presence of said complexes as an indication of the antibody specific for the BS322 antigen.

68. (Amended). The method of claim 67, wherein the [polynucleotide] polypeptide is attached to a solid phase.

70. (Amended). A method for producing antibodies which specifically bind to BS322 antigen, said method comprising:

administering to an individual an isolated immunogenic polypeptide in an amount sufficient to elicit an immune response,

wherein said immunogenic polypeptide comprises at least one amino acid sequence [BS322 epitope and is] selected from the group consisting of: SEQ ID NO[S]:24[-28 and degenerate codon equivalents thereof] SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, and SEQ ID NO: 28.

72. (Amended). An isolated [DNA molecule] polypeptide[,] selected from the group consisting of: SEQ ID NO[S]:24[-28 and degenerate codon equivalents thereof] SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27 and SEQ ID NO: 28.

73. (Amended). The polypeptide [DNA molecule] of claim 72, wherein said molecule is produced by recombinant techniques.

74. (Amended). The polypeptide [DNA molecule] of claim 72, wherein said molecule is produced by synthetic techniques.

75. (Amended). A test kit for determining if BS322 antigen or anti-BS322 antibody is present in a test sample, said kit comprising:

a container containing at least one isolated [DNA molecule] polypeptide selected from the group consisting of SEQ ID NO[S]:24[-28 and degenerate codon equivalents thereof] SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, and SEQ ID NO: 28.

76. (Amended). The test kit of claim 75, wherein the polypeptide [DNA molecule] is attached to a solid phase.

80. (Amended). A method for producing antibodies which specifically bind to BS322 antigen, comprising:

administering to an individual an isolated immunogenic polypeptide in an amount sufficient to elicit an immune response,

wherein said immunogenic polypeptide is [a DNA molecule] selected from the group consisting of: SEQ ID NO[S]:24[-28 and degenerate codon equivalents thereof] SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, and SEQ ID NO: 28.



#28/dec.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Billing-Medel, et al.
Serial No.: 09/489,079
Filed: January 21, 2000
For: Reagents and Methods Useful For
Detecting Diseases of the
Breast
Attorney Docket No.: 6451.US.P1
Examiner: J. Epps
Group Art Unit: 1635

Certificate of Mailing (37 CFR 1.8(a)):

I hereby certify that this paper
(along with any paper referred to as
being attached or enclosed) is being
sent by first class mail to the
Commissioner for Patents, Washington
D.C., 20231 on January 27, 2003.

Wanda C. Smith
Wanda E. Smith

DECLARATION UNDER 37 C.F.R. SECTION 1.132 of EDWARD GRANADOS

Commissioner for Patents
Washington, D.C. 20231

Sir:

I, Edward Granados, declare:

1. I am one skilled in the art of cancer diagnostics. I have a Ph.D. in chemistry from the State University of New York at Buffalo, and an M.A. and B.A., also in Chemistry, from the State University of New York at Oneonta.

2. I have worked at Abbott Laboratories in the Diagnostics Division for eighteen years. My responsibilities include: the development of new diagnostic technologies and the discovery and validation of novel cancer markers to improve the accuracy of diagnosing the onset of cancer.

3. I have also authored numerous patents and publications relating to cancer markers. (See Exhibit A).

RECEIVED
FEB 05 2003
TECH CENTER 1600/2900

4. I prepared an alignment between BS322 and NY-BR-1 (AF269087). The alignment was prepared using the software program Sequencher (Version 4) which is commercially available from Gene Codes Corporation, 640 Avis Drive, Ann Arbor, MI 48108. The primers used (and which are described in *Cancer Research*, 61:2055-2061 (March 1, 2001) were:

primer BR-1A TCTCATAGATGCTGGTGCTGATC

primer BR1.1B CCCAGACATTGAATTTTGGCAGAC

5. BS322 contains 2683 nucleotides (see the consensus sequence shown in SEQ ID NO:9 of the above-identified application) and NY-BR-1 contains 4466 nucleotides. Based upon the alignment that I prepared as described above in Paragraph 4, I prepared the contig map shown in attached Exhibit B. The contig shows that BS322 is missing a single stretch of 185 nucleotides that are present in NY-BR-1. These nucleotides are missing between position 1198 and 1199 of BS322. The missing piece is nucleotides 3015 thru 3198 of NY-BR-1 (AF269087). Also, the first 45 bases of BS322 are 44.4 percent identical to AF269087). The remaining bases were 99.2% identical (see attached Exhibit C).

6. I prepared an amino acid sequence alignment between SEQ ID NOS: 24 and 25 of the above-identified application and NY-BR-1 (see attached Exhibit D). The alignment was prepared using the Pileup and Pretty alignment programs that are part of the Wisconsin Package. The Wisconsin Package is a compilation of genomic and proteomic programs that is a product of Accelrys, San Diego, California.

7. In the alignment shown in Exhibit D, capital letters represent matches and small letters represent mismatches in

the alignment. For SEQ ID NO:24, the matches begin at amino acid 592 of NY-BR-1. There are 5 mismatches until amino acid 972 and at the end, only 1 out of the remaining 16 amino acids contain a mismatch. For SEQ ID NO:25, beginning at amino acid 1025 of NY-BR-1, there are 9 mismatches initially, and then the remainder of the sequence is a complete match.

8. I hereby declare that all statements made herein are of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that the statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and such willful false statements may jeopardize the validity of the application or any patent issued thereon.


Edward Granados



Date



EXHIBIT A

PATENTS

US6465181 10/15/2002 Reagents and methods useful for detecting diseases of the prostate
US6391543 05/21/2002 Reagents and methods useful for detecting diseases of the prostate
US6350583 02/26/2002 Reagents and methods useful for detecting diseases of the prostate
US6252047 06/26/2001 Reagents and methods useful for detecting diseases of the prostate
US6232456 05/15/2001 Serine protease reagents and methods useful for detecting and treating diseases of the prostate
US6203992 03/20/2001 Nucleic acid primers and probes for detecting tumor cells
US6183952 02/06/2001 Reagents and methods useful for detecting diseases of the breast
US6130043 10/10/2000 Reagents and methods useful for detecting diseases of the prostate
US5955268 09/21/1999 Method and reagent for detecting multiple nucleic acid sequences in a test sample
US5637472 06/10/1997 Hydrazine derivitized cells
US5591598 01/07/1997 Method for quantitating hydrazine groups
US5229268 07/20/1993 Method for diagnostic immunoassay by solid phase separation

PUBLICATIONS

Colpitts TL, Billing-Medel P, Granados EN, Hayden M, Hodges S, Menhart N, Roberts L, Russel J., Stroupe SD. Mammaglobin is found in breast tissue as a complex with BU101.

Colpitts TL, Billing-Medel P, Friedman P, Granados EN, Hodges S, Menhart N, Roberts L, Russel J., Stroupe SD. Mammaglobin complexes with BU101 in breast tissue. AnnNY Acad Sci. 2000; 923: 312-5. Biochemistry, 2001 Sep 18;40(37):11048-59>

Methylated poly(L-lysine): Conformational effects and interactions with polynucleotides. Bello J; Granados EN; Lewinski S; Bello HR; Trueheart T. J Biomol Struct Dyn 2(5) p899-913, 1985.

Preparation and assay of poly ICL-CM dextran, an interferon inducer of reduced toxicity. Bello J; Granados EN; McGarry M; O'Malley J. Methods Enzymol 119 p103-106, 1986.

Purification of carboxymethylcellulose decreases toxicity of poly ICLC in mice. Bello J; O'Malley J; Granados EN. J Interferon Res 5(3) p429-30, 1985.

Poly ICL-CM dextran: An interferon inducer of reduced toxicity. Granados EN; Dawidzik J; O'Malley; McGarry M; Bello J. J Interferon Res 4(2) p155-160, 1984.

Poly ICLC induces anti-IC antibodies in mice and rabbits. Granados EN; Alm; O'Malley; McGarry M; Bello J. J Interferon Res 4(1) p57-62, 1984.

Human serum digests poly(rI) . poly(rC) differently from other mammalian sera. Granados EN; Lewinski S; O'Malley J; Bello J.J Interferon Res 4(1) p51-55,1984.

Conformation and aggregation of melittin: Dependence on pH and concentration. Bello J; Bello HR; Granados EN. Biochemistry 21(3) p461-5,1982.

Interactions of poly(trimethyllysine) and poly(lysine) with polynucleotides: Circular dichroism and A-T sequence selectivity. Granados, EN; Bello J. Biochemistry 20(16) p4761-4765,1981.

Interactions of poly(trimethyllysine) and poly(ornithine) with polynucleotides: Salt dissociation and thermal denaturation. Granados EN; Bello J. Biochemistry 19(14) p3227-3233,1980.

Alkylated poly-amino part I: Conformational properties of poly-n-epsilon trimethyl-L-lysine and poly-n-delta trimethyl-L-ornithine. Granados EN; Bello J. Biopolymers 18 (6) p1479-1486,1979.

Enhanced Sensitivity Assay for the TDx Analyzer. Grenier F; Schick B; Granados E; Kolaczowski L; Pry T. Clin Chem 33 (9) p1570,1987.

TDx-R Digoxin III A non-extraction immunoassay for serum digoxin. Grenier, F Schick B; Granados E; Wang N; Hansen J; Pry T. Clin Chem 33 (6) p923, 1987.



EXHIBIT B






EXHIBIT C

>AF269087	#1	CTAGTCTATA CCAGCAACGA CTCCTACATC
	
	#1	CTAGTCTATA CCAGCAACGA CTCCTACATC
>AF269087	#31	GTCCACTCTG GGGATCTTAG AAAGATCCAT
	
	#31	GTCCACTCTG GGGATCTTAG AAAGATCCAT
>AF269087	#61	AAAGCTGCCT CCCGGGGACA AGTCCGGAAG
	
	#61	AAAGCTGCCT CCCGGGGACA AGTCCGGAAG
>AF269087	#91	CTGGAGAAGA TGACAAAGAG GAAGAAGACC
	
	#91	CTGGAGAAGA TGACAAAGAG GAAGAAGACC
>AF269087	#121	ATCAACCTTA ATATACAAGA CGCCCAGAAG
	
	#121	ATCAACCTTA ATATACAAGA CGCCCAGAAG
>AF269087	#151	AGGACTGCTC TACACTGGGC CTGTGTCAAT
	
	#151	AGGACTGCTC TACACTGGGC CTGTGTCAAT
>AF269087	#181	GGCCATGAGG AAGTAGTAAC ATTTCTGGTA
	
	#181	GGCCATGAGG AAGTAGTAAC ATTTCTGGTA
>AF269087	#211	GACAGAAAGT GCCAGCTTGA CGTCCTTGAT
	

	#211	GACAGAAAGT GCCAGCTTGA CGTCCTTGAT
>AF269087	#241	GGCGAACACA GGACACCTCT GATGAAGGCT
	
	#241	GGCGAACACA GGACACCTCT GATGAAGGCT
>AF269087	#271	CTACAATGCC ATCAGGAGGC TTGTGCAAAT
	
	#271	CTACAATGCC ATCAGGAGGC TTGTGCAAAT
>AF269087	#301	ATTCTGATAG ATTCTGGTGC CGATATAAAT
	
	#301	ATTCTGATAG ATTCTGGTGC CGATATAAAT
>AF269087	#331	CTCGTAGATG TGTATGGCAA CATGGCTCTC
	
	#331	CTCGTAGATG TGTATGGCAA CATGGCTCTC
>AF269087	#361	CATTATGCTG TTTATAGTGA GATTTTGTCA
	
	#361	CATTATGCTG TTTATAGTGA GATTTTGTCA
>AF269087	#391	GTGGTGGCAA AACTGCTGTC CCATGGTGCA
	
	#391	GTGGTGGCAA AACTGCTGTC CCATGGTGCA
>AF269087	#421	GTCATCGAAG TGCACAACAA GGCTAGCCTC
	
	#421	GTCATCGAAG TGCACAACAA GGCTAGCCTC
>AF269087	#451	ACACCACTTT TACTATCCAT AACGAAAAGA
	
	#451	ACACCACTTT TACTATCCAT AACGAAAAGA

>AF269087	#481	AGTGAGCAAA TTGTGGAATT TTTGCTGATA
	
	#481	AGTGAGCAAA TTGTGGAATT TTTGCTGATA
>AF269087	#511	AAAAATGCAA ATGCGAATGC AGTTAATAAG
	
	#511	AAAAATGCAA ATGCGAATGC AGTTAATAAG
>AF269087	#541	TATAAATGCA CAGCCCTCAT GCTTGCTGTA
	
	#541	TATAAATGCA CAGCCCTCAT GCTTGCTGTA
>AF269087	#571	TGTCATGGAT CATCAGAGAT AGTTGGCATG
	
	#571	TGTCATGGAT CATCAGAGAT AGTTGGCATG
>AF269087	#601	CTTCTTCAGC AAAATGTTGA CGTCTTTGCT
	
	#601	CTTCTTCAGC AAAATGTTGA CGTCTTTGCT
>AF269087	#631	GCAGATATAT GTGGAGTAAC TGCAGAACAT
	
	#631	GCAGATATAT GTGGAGTAAC TGCAGAACAT
>AF269087	#661	TATGCTGTTA CTTGTGGATT TCATCACATT
	
	#661	TATGCTGTTA CTTGTGGATT TCATCACATT
>AF269087	#691	CATGAACAAA TTATGGAATA TATACGAAAA
	
	#691	CATGAACAAA TTATGGAATA TATACGAAAA

>AF269087	#721	TTATCTAAAA ATCATCAAAA TACCAATCCA
	
	#721	TTATCTAAAA ATCATCAAAA TACCAATCCA
>AF269087	#751	GAAGGAACAT CTGCAGGAAC ACCTGATGAG
	
	#751	GAAGGAACAT CTGCAGGAAC ACCTGATGAG
>AF269087	#781	GCTGCACCCT TGGCGGAAAG AACACCTGAC
	
	#781	GCTGCACCCT TGGCGGAAAG AACACCTGAC
>AF269087	#811	ACAGCTGAAA GCTTGGTGGA AAAACACCT
	
	#811	ACAGCTGAAA GCTTGGTGGA AAAACACCT
>AF269087	#841	GATGAGGCTG CACCCTTGGT GGAAAGAACA
	
	#841	GATGAGGCTG CACCCTTGGT GGAAAGAACA
>AF269087	#871	CCTGACACGG CTGAAAGCTT GGTGGAAAAA
	
	#871	CCTGACACGG CTGAAAGCTT GGTGGAAAAA
>AF269087	#901	ACACCTGATG AGGCTGCATC CTTGGTGGAG
	
	#901	ACACCTGATG AGGCTGCATC CTTGGTGGAG
>AF269087	#931	GGAACATCTG ACAAATTCA ATGTTTGGAG
	
	#931	GGAACATCTG ACAAATTCA ATGTTTGGAG

>AF269087	#961	AAAGCGACAT CTGGAAAGTT CGAACAGTCA
	
	#961	AAAGCGACAT CTGGAAAGTT CGAACAGTCA
>AF269087	#991	GCAGAAGAAA CACCTAGGGA AATTACGAGT
	
	#991	GCAGAAGAAA CACCTAGGGA AATTACGAGT
>AF269087	#1021	CCTGCAAAAG AAACATCTGA GAAATTTACG
	
	#1021	CCTGCAAAAG AAACATCTGA GAAATTTACG
>AF269087	#1051	TGGCCAGCAA AAGGAAGACC TAGGAAGATC
	
	#1051	TGGCCAGCAA AAGGAAGACC TAGGAAGATC
>AF269087	#1081	GCATGGGAGA AAAAAGAAGA CACACCTAGG
	
	#1081	GCATGGGAGA AAAAAGAAGA CACACCTAGG
>AF269087	#1111	GAAATTATGA GTCCCGCAA AGAAACATCT
	
	#1111	GAAATTATGA GTCCCGCAA AGAAACATCT
>AF269087	#1141	GAGAAATTTA CGTGGGCAGC AAAAGGAAGA
	
	#1141	GAGAAATTTA CGTGGGCAGC AAAAGGAAGA
>AF269087	#1171	CCTAGGAAGA TCGCATGGGA GAAAAAAGAA
	
	#1171	CCTAGGAAGA TCGCATGGGA GAAAAAAGAA
>AF269087	#1201	ACACCTGTAA AGACTGGATG CGTGGCAAGA

```

#1201      .....
            ACACCTGTAA AGACTGGATG CGTGGCAAGA

>AF269087  #1231      GTAACATCTA ATAAACTAA AGTTTTGGAA
            .....
            #1231      GTAACATCTA ATAAACTAA AGTTTTGGAA

>AF269087  #1261      AAAGGAAGAT CTAAGATGAT TGCATGTCCT
            .....
            #1261      AAAGGAAGAT CTAAGATGAT TGCATGTCCT

>AF269087  #1291      ACAAAGAAT CATCTACAAA AGCAAGTGCC
            .....
            #1291      ACAAAGAAT CATCTACAAA AGCAAGTGCC

>AF269087  #1321      AATGATCAGA GGT'TCCCATC AGAATCCAAA
            .....
            #1321      AATGATCAGA GGT'TCCCATC AGAATCCAAA

>AF269087  #1351      CAAGAGGAAG ATGAAGAATA TTCTTGTGAT
            .....
            #1351      CAAGAGGAAG ATGAAGAATA TTCTTGTGAT

>AF269087  #1381      TCTCGGAGTC TCTTTGAGAG TTCTGCAAAG
            .....
            #1381      TCTCGGAGTC TCTTTGAGAG TTCTGCAAAG

>AF269087  #1411      ATTCAAGTGT GTATACCTGA GTCTATATAT
            .....
            #1411      ATTCAAGTGT GTATACCTGA GTCTATATAT

>AF269087  #1441      CAAAAAGTAA TGGAGATAAA TAGAGAAGTA
            .....

```

	#1441	CAAAAAGTAA TGGAGATAAA TAGAGAAGTA
>AF269087	#1471	GAAGAGCCTC CTAAGAAGCC ATCTGCCTTC
	
	#1471	GAAGAGCCTC CTAAGAAGCC ATCTGCCTTC
>AF269087	#1501	AAGCCTGCCA TTGAAATGCA AAACCTCTGTT
	
	#1501	AAGCCTGCCA TTGAAATGCA AAACCTCTGTT
>AF269087	#1531	CCAAATAAAG CCTTTGAATT GAAGAATGAA
	
	#1531	CCAAATAAAG CCTTTGAATT GAAGAATGAA
>AF269087	#1561	CAAACATTGA GAGCAGATCC GATGTTCCCA
	
	#1561	CAAACATTGA GAGCAGATCC GATGTTCCCA
>AF269087	#1591	CCAGAATCCA AACAAAAGGA CTATGAAGAA
	
	#1591	CCAGAATCCA AACAAAAGGA CTATGAAGAA
>AF269087	#1621	AATTCTTGGG ATTCTGAGAG TCTCTGTGAG
	
	#1621	AATTCTTGGG ATTCTGAGAG TCTCTGTGAG
>AF269087	#1651	ACTGTTTCAC AGAAGGATGT GTGTTTACCC
	
	#1651	ACTGTTTCAC AGAAGGATGT GTGTTTACCC
>AF269087	#1681	AAGGCTACAC ATCAAAAAGA AATAGATAAA
	
	#1681	AAGGCTACAC ATCAAAAAGA AATAGATAAA

```

>AF269087      #1711      ATAAATGGAA AATTAGAAGA GTCTCCTAAT
.....
#1711          ATAAATGGAA AATTAGAAGA GTCTCCTAAT

>AF269087      #1741      AAAGATGGTC TTCTGAAGGC TACCTGCGGA
.....
#1741          AAAGATGGTC TTCTGAAGGC TACCTGCGGA

>AF269087      #1771      ATGAAAGTTT CTATTCCAAC TAAAGCCTTA
.....
#1771          ATGAAAGTTT CTATTCCAAC TAAAGCCTTA

>AF269087      #1801      GAATTGAAGG ACATGCAAAC TTTCAAAGCG
>BS322.1 to 1198 >#1>          AGTATAC ATTCTTTATT
.....
#1801          GAATTGAAGG ACAWGYAWAC WTTTCWWWRYK
                      * * * * *

>AF269087      #1831      GAGCCTCCGG GGAAGCCATC TGCCTTCGAG
>BS322.1 to 1198 #18        AATCAT:.TT TGCTTCCAAC :CCCATTTAG
.....
#1831          RAKCMTCCCK KGMWKCCAWC TSCCWYKAG
* * * * * * * * * *

>AF269087      #1861      CCTGCCACTG AAATGCAAAA GTCTGTCCCA
>BS322.1 to 1198 #48        CCTGCCATTG AAATGCAAAA GTCTGTTCCTA
.....
#1861          CCTGCCAYTG AAATGCAAAA GTCTGTYCCA
                      *                               *

>AF269087      #1891      AATAAAGCCT TGGAATTGAA AAATGAACAA
>BS322.1 to 1198 #78        AATAAAGCCT TGGAATTGAA GAATGAACAA
.....
#1891          AATAAAGCCT TGGAATTGAA RAATGAACAA
                      *

```

>AF269087	#1921	ACATGGAGAG CAGATGAGAT ACTCCCATCA
>BS322 1 to 1198	#108	ACATTGAGAG CAGATGAGAT ACTCCCATCA
	
	#1921	ACATKGAGAG CAGATGAGAT ACTCCCATCA
		*
>AF269087	#1951	GAATCCAAAC AAAAGGACTA TGAAGAAAAT
>BS322 1 to 1198	#138	GAATCCAAAC AAAAGGACTA TGAAGAAAGT
	
	#1951	GAATCCAAAC AAAAGGACTA TGAAGAAART
		*
>AF269087	#1981	TCTTGGGATA CTGAGAGTCT CTGTGAGACT
>BS322 1 to 1198	#168	TCTTGGGATT CTGAGAGTCT CTGTGAGACT
	
	#1981	TCTTGGGATW CTGAGAGTCT CTGTGAGACT
		*
>AF269087	#2011	GTTTCACAGA AGGATGTGTG TTTACCCAAG
>BS322 1 to 1198	#198	GTTTCACAGA AGGATGTGTG TTTACCCAAG
	
	#2011	GTTTCACAGA AGGATGTGTG TTTACCCAAG
>AF269087	#2041	GCTGCGCATC AAAAAGAAAT AGATAAAATA
>BS322 1 to 1198	#228	GCTGCGCATC AAAAAGAAAT AGATAAAATA
	
	#2041	GCTGCGCATC AAAAAGAAAT AGATAAAATA
>AF269087	#2071	AATGGAAAAT TAGAAGGGTC TCCTGTTAAA
>BS322 1 to 1198	#258	AATGGAAAAT TAGAAGGGTC TCCTGTTAAA
	
	#2071	AATGGAAAAT TAGAAGGGTC TCCTGTTAAA
>AF269087	#2101	GATGGTCTTC TGAAGGCTAA CTGCGGAATG
>BS322 1 to 1198	#288	GATGGTCTTC TGAAGGCTAA CTGCGGAATG
	
	#2101	GATGGTCTTC TGAAGGCTAA CTGCGGAATG

>AF269087	#2131	AAAGTTTCTA TTCCAACATA AGCCTTAGAA
>BS322 1 to 1198	#318	AAAGTTTCTA TTCCAACATA AGCCTTAGAA
	 ⁵
	#2131	AAAGTTTCTA TTCCAACATA AGCCTTAGAA
>AF269087	#2161	TTGATGGACA TGCAAACATT CAAAGCAGAG
>BS322 1 to 1198	#348	TTGATGGACA TGCAAACATT CAAAGCAGAG
	
	#2161	TTGATGGACA TGCAAACATT CAAAGCAGAG
>AF269087	#2191	CCTCCCGAGA AGCCATCTGC CTTCGAGCCT
>BS322 1 to 1198	#378	CCTCCCGAGA AGCCATCTGC CTTCGAGCCT
	
	#2191	CCTCCCGAGA AGCCATCTGC CTTCGAGCCT
>AF269087	#2221	GCCATTGAAA TGCAAAGTC TGTTCCAAAT
>BS322 1 to 1198	#408	GCCATTGAAA TGCAAAGTC TGTTCCAAAT
	
	#2221	GCCATTGAAA TGCAAAGTC TGTTCCAAAT
>AF269087	#2251	AAAGCCTTGG AATTGAAGAA TGAACAAACA
>BS322 1 to 1198	#438	AAAGCCTTGG AATTGAAGAA TGAACAAACA
	
	#2251	AAAGCCTTGG AATTGAAGAA TGAACAAACA
>AF269087	#2281	TTGAGAGCAG ATGAGATACT CCCATCAGAA
>BS322 1 to 1198	#468	TTGAGAGCAG ATGAGATACT CCCATCAGAA
	
	#2281	TTGAGAGCAG ATGAGATACT CCCATCAGAA
>AF269087	#2311	TCCAAACAAA AGGACTATGA AGAAAGTTCT
>BS322 1 to 1198	#498	TCCAAACAAA AGGACTATGA AGAAAGTTCT
	
	#2311	TCCAAACAAA AGGACTATGA AGAAAGTTCT

>AF269087	#2341	TGGGATTCTG AGAGTCTCTG TGAGACTGTT
>BS322 1 to 1198	#528	TGGGATTCTG AGAGTCTCTG TGAGACTGTT
	
	#2341	TGGGATTCTG AGAGTCTCTG TGAGACTGTT
>AF269087	#2371	TCACAGAAGG ATGTGTGTTT ACCCAAGGCT
>BS322 1 to 1198	#558	TCACAGAAGG ATGTGTGTTT ACCCAAGGCT
	
	#2371	TCACAGAAGG ATGTGTGTTT ACCCAAGGCT
>AF269087	#2401	ACACATCAAA AAGAAATAGA TAAATAAAT
>BS322 1 to 1198	#588	ACACATCAAA AAGAAATAGA TAAATAAAT
	
	#2401	ACACATCAAA AAGAAATAGA TAAATAAAT
>AF269087	#2431	GGAAAATTAG AAGAGTCTCC TGATAATGAT
>BS322 1 to 1198	#618	GGAAAATTAG AAGAGTCTCC TGATAATGAT
	
	#2431	GGAAAATTAG AAGAGTCTCC TGATAATGAT
>AF269087	#2461	GGTTTTCTGA AGGCTCCCTG CAGAATGAAA
>BS322 1 to 1198	#648	GGTTTTCTGA AGGCTCCCTG CAGAATGAAA
	
	#2461	GGTTTTCTGA AGGCTCCCTG CAGAATGAAA
>AF269087	#2491	GTTTCTATTG CAACTAAAGC CTTAGAATTG
>BS322 1 to 1198	#678	GTTTCTATTG CAACTAAAGC CTTAGAATTG
	
	#2491	GTTTCTATTG CAACTAAAGC CTTAGAATTG
>AF269087	#2521	ATGGACATGC AAACTTTCAA AGCAGAGCCT
>BS322 1 to 1198	#708	ATGGACATGC AAACTTTCAA AGCAGAGCCT
	

	#2521	ATGGACATGC AAAC TTTCAA AGCAGAGCCT
>AF269087	#2551	CCCGAGAAGC CATCTGCCTT CGAGCCTGCC
>BS322 1 to 1198	#738	CCCGAGAAGC CATCTGCCTT CGAGCCTGCC
	
	#2551	CCCGAGAAGC CATCTGCCTT CGAGCCTGCC
>AF269087	#2581	ATTGAAATGC AAAAGTCTGT TCCAAATAAA
>BS322 1 to 1198	#768	ATTGAAATGC AAAAGTCTGT TCCAAATAAA
	
	#2581	ATTGAAATGC AAAAGTCTGT TCCAAATAAA
>AF269087	#2611	GCCTTGGAAT TGAAGAATGA ACAAACATTG
>BS322 1 to 1198	#798	GCCTTGGAAT TGAAGAATGA ACAAACATTG
	
	#2611	GCCTTGGAAT TGAAGAATGA ACAAACATTG
>AF269087	#2641	AGAGCAGATC AGATGTTCCC TTCAGAATCA
>BS322 1 to 1198	#828	AGAGCAGATC AGATGTTCCC TTCAGAATCA
	
	#2641	AGAGCAGATC AGATGTTCCC TTCAGAATCA
>AF269087	#2671	AAACAAAAGA AGGTTGAAGA AAATTCCTTG
>BS322 1 to 1198	#858	AAACAAAAGA ACGTTGAAGA AAATTCCTTG
	
	#2671	AAACAAAAGA ASGTTGAAGA AAATTCCTTG
		*
>AF269087	#2701	GATTCTGAGA GTCTCCGTGA GACTGTTTCA
>BS322 1 to 1198	#888	GATTCTGAGA GTCTCCGTGA GACTGTTTCA
	
	#2701	GATTCTGAGA GTCTCCGTGA GACTGTTTCA
>AF269087	#2731	CAGAAGGATG TGTGTGTACC CAAGGCTACA
>BS322 1 to 1198	#918	CAGAAGGATG TGTGTGTACC CAAGGCTACA

```

.....
#2731 CAGAAGGATG TGTGTGTACC CAAGGCTACA

>AF269087 #2761 CATCAAAAAG AAATGGATAA AATAAGTGGA
>BS322 1 to 1198 #948 CATCAAAAAG AAATGGATAA AATAAGTGGA
#2761 CATCAAAAAG AAATGGATAA AATAAGTGGA

>AF269087 #2791 AAATTAGAAG ATTCAACTAG CCTATCAAAA
>BS322 1 to 1198 #978 AAATTAGAAG ATTCAACTAG CCTATCAAAA
#2791 AAATTAGAAG ATTCAACTAG CCTATCAAAA

>AF269087 #2821 ATCTTGGATA CAGTTCATTC TTGTGAAAGA
>BS322 1 to 1198 #1008 ATCTTGGATA CAATTCATTC TTGTGAAAGA
#2821 ATCTTGGATA CARTTCATTC TTGTGAAAGA
*

>AF269087 #2851 GCAAGGGAAC TTCAAAAAGA TCACTGTGAA
>BS322 1 to 1198 #1038 GCAAGGGAAC TTCAAAAAGA TCACTGTGAA
#2851 GCAAGGGAAC TTCAAAAAGA TCACTGTGAA

>AF269087 #2881 CAACGTACAG GAAAAATGGA ACAAATGAAA
>BS322 1 to 1198 #1068 CAATGTACAG GAAAAATGGA ACAAATGAAA
#2881 CAAYGTACAG GAAAAATGGA ACAAATGAAA
*

>AF269087 #2911 AAGAAGTTTT GTGTACTGAA AAAGAACTG
>BS322 1 to 1198 #1098 AAGAAGTTTT GTGTACTGAA AAAGAACTG
#2911 AAGAAGTTTT GTGTACTGAA AAAGAACTG

>AF269087 #2941 TCAGAAGCAA AAGAAATAAA ATCACAGTTA

```

>BS322 1 to 1198	#1128	TCAGAAGCAA AAGAAATAAA ATCACAGTTA
	
	#2941	TCAGAAGCAA AAGAAATAAA ATCACAGTTA
>AF269087	#2971	GAGAACCAAA AAGTTAAATG GGAACAAGAG
>BS322 1 to 1198	#1158	GAGAACCAAA AAGTTAAATG GGAACAAGAG
	
	#2971	GAGAACCAAA AAGTTAAATG GGAACAAGAG
>AF269087	#3001	CTCTGCAGTG TGAGATTGAC TTTAAACCAA
>BS322 1 to 1198	#1188	CTCTGCAGTG TGAG
	
	#3001	CTCTGCAGTG TGAGATTGAC TTTAAACCAA
>AF269087	#3031	GAAGAAGAGA AGAGAAGAAA TGCCGATATA
	
	#3031	GAAGAAGAGA AGAGAAGAAA TGCCGATATA
>AF269087	#3061	TTAAATGAAA AAATTAGGGA AGAATTAGGA
	
	#3061	TTAAATGAAA AAATTAGGGA AGAATTAGGA
>AF269087	#3091	AGAATCGAAG AGCAGCATAG GAAAGAGTTA
	
	#3091	AGAATCGAAG AGCAGCATAG GAAAGAGTTA
>AF269087	#3121	GAAGTGAAAC AACAACTTGA ACAGGCTCTC
	
	#3121	GAAGTGAAAC AACAACTTGA ACAGGCTCTC
>AF269087	#3151	AGAATACAAG ATATAGAATT GAAGAGTGTA
	
	#3151	AGAATACAAG ATATAGAATT GAAGAGTGTA

>BS322 1199 to 2683 >#1>		GT TTCTCACACT
>AF269087	#3181	GAAAGTAATT TGAATCAGGT TTCTCACACT
	
	#3181	GAAAGTAATT TGAATCAGGT TTCTCACACT
>BS322 1199 to 2683 #13		CATGAAAATG AAAATTATCT CTTACATGAA
>AF269087	#3211	CATGAAAATG AAAATTATCT CTTACATGAA
	
	#3211	CATGAAAATG AAAATTATCT CTTACATGAA
>BS322 1199 to 2683 #43		AATTGCATGT TGAAAAAGGA AATTGCCATG
>AF269087	#3241	AATTGCATGT TGAAAAAGGA AATTGCCATG
	
	#3241	AATTGCATGT TGAAAAAGGA AATTGCCATG
>BS322 1199 to 2683 #73		CTAAAACTGG AAATAGCCAC ACTGAAACAC
>AF269087	#3271	CTAAAACTGG AAATAGCCAC ACTGAAACAC
	
	#3271	CTAAAACTGG AAATAGCCAC ACTGAAACAC
>BS322 1199 to 2683 #103		CAATACCAGG AAAAGGAAAA TAAATACTTT
>AF269087	#3301	CAATACCAGG AAAAGGAAAA TAAATACTTT
	
	#3301	CAATACCAGG AAAAGGAAAA TAAATACTTT
>BS322 1199 to 2683 #133		GAGGACATTA AGATTTTAAA AGAAAAGAAT
>AF269087	#3331	GAGGACATTA AGATTTTAAA AGAAAAGAAT
	
	#3331	GAGGACATTA AGATTTTAAA AGAAAAGAAT
>BS322 1199 to 2683 #163		GCTGAACTTC AGATGACCCT AAAACTGAAA
>AF269087	#3361	GCTGAACTTC AGATGACCCT AAAACTGAAA
	
	#3361	GCTGAACTTC AGATGACCCT AAAACTGAAA

>BS322 1199 to 2683 #193	GAGGAATCAT TAACTAAAAG GGCATCTCAA
>AF269087 #3391	GAGGAATCAT TAACTAAAAG GGCATCTCAA

#3391	GAGGAATCAT TAACTAAAAG GGCATCTCAA
>BS322 1199 to 2683 #223	TATAGTGGGC AGCTTAAAGT TCTGATAGCT
>AF269087 #3421	TATAGTGGGC AGCTTAAAGT TCTGATAGCT

#3421	TATAGTGGGC AGCTTAAAGT TCTGATAGCT
>BS322 1199 to 2683 #253	GAGAACACAA TGCTCACTTC TAAATTGAAG
>AF269087 #3451	GAGAACACAA TGCTCACTTC TAAATTGAAG

#3451	GAGAACACAA TGCTCACTTC TAAATTGAAG
>BS322 1199 to 2683 #283	GAAAAACAAG ACAAAGAAAT ACTAGAGGCA
>AF269087 #3481	GAAAAACAAG ACAAAGAAAT ACTAGAGGCA

#3481	GAAAAACAAG ACAAAGAAAT ACTAGAGGCA
>BS322 1199 to 2683 #313	GAAATTGAAT CACACCATCC TAGACTGGCT
>AF269087 #3511	GAAATTGAAT CACACCATCC TAGACTGGCT

#3511	GAAATTGAAT CACACCATCC TAGACTGGCT
>BS322 1199 to 2683 #343	TCTGCTGTAC AAGACCATGA TCAAATTGTG
>AF269087 #3541	TCTGCTGTAC AAGACCATGA TCAAATTGTG

#3541	TCTGCTGTAC AAGACCATGA TCAAATTGTG
>BS322 1199 to 2683 #373	ACATCAAGAA AAAGTCAAGA ACCTGCTTTC
>AF269087 #3571	ACATCAAGAA AAAGTCAAGA ACCTGCTTTC

#3571	ACATCAAGAA AAAGTCAAGA ACCTGCTTTC
>BS322 1199 to 2683 #403	CACATTGCAG GAGATGCTTG TTTGCAAAGA
>AF269087 #3601	CACATTGCAG GAGATGCTTG TTTGCAAAGA

#3601	CACATTGCAG GAGATGCTTG TTTGCAAAGA
>BS322 1199 to 2683 #433	AAAATGAATG TTGATGTGAG TAGTACGATA
>AF269087 #3631	AAAATGAATG TTGATGTGAG TAGTACGATA

#3631	AAAATGAATG TTGATGTGAG TAGTACGATA
>BS322 1199 to 2683 #463	TATAACAATG AGGTGCTCCA TCAACCACTT
>AF269087 #3661	TATAACAATG AGGTGCTCCA TCAACCACTT

#3661	TATAACAATG AGGTGCTCCA TCAACCACTT
>BS322 1199 to 2683 #493	TCTGAAGCTC AAAGGAAATC CAAAAGCCTA
>AF269087 #3691	TCTGAAGCTC AAAGGAAATC CAAAAGCCTA

#3691	TCTGAAGCTC AAAGGAAATC CAAAAGCCTA
>BS322 1199 to 2683 #523	AAAATTAATC TCAATTATGC AGGAGATGCT
>AF269087 #3721	AAAATTAATC TCAATTATGC AGGAGATGCT

#3721	AAAATTAATC TCAATTATGC AGGAGATGCT
>BS322 1199 to 2683 #553	CTAAGAGAAA ATACATTGGT TTCAGAACAT
>AF269087 #3751	CTAAGAGAAA ATACATTGGT TTCAGAACAT

#3751	CTAAGAGAAA ATACATTGGT TTCAGAACAT
>BS322 1199 to 2683 #583	GCACAAAGAG ACCAACGTGA AACACAGTGT
>AF269087 #3781	GCACAAAGAG ACCAACGTGA AACACAGTGT

```

#3781 GCACAAAGAG ACCAACGTGA AACACAGTGT

>BS322 1199 to 2683 #613 CAAATGAAGG AAGCTGAACA CATGTATCAA
>AF269087 #3811 CAAATGAAGG AAGCTGAACA CATGTATCAA
#3811 CAAATGAAGG AAGCTGAACA CATGTATCAA

>BS322 1199 to 2683 #643 AACGAACAAG ATAATGTGAA CAAACACACT
>AF269087 #3841 AACGAACAAG ATAATGTGAA CAAACACACT
#3841 AACGAACAAG ATAATGTGAA CAAACACACT

>BS322 1199 to 2683 #673 GAACAGCAGG AGTCTCTAGA TCAGAAATTA
>AF269087 #3871 GAACAGCAGG AGTCTCTAGA TCAGAAATTA
#3871 GAACAGCAGG AGTCTCTAGA TCAGAAATTA

>BS322 1199 to 2683 #703 TTTCAACTAC AAAGCAAAAA TATGTGGCTT
>AF269087 #3901 TTTCAACTAC AAAGCAAAAA TATGTGGCTT
#3901 TTTCAACTAC AAAGCAAAAA TATGTGGCTT

>BS322 1199 to 2683 #733 CAACAGCAAT TAGTTCATGC ACATAAGAAA
>AF269087 #3931 CAACAGCAAT TAGTTCATGC ACATAAGAAA
#3931 CAACAGCAAT TAGTTCATGC ACATAAGAAA

>BS322 1199 to 2683 #763 GCTGACAACA AAAGCAAGAT AACAAATTGAT
>AF269087 #3961 GCTGACAACA AAAGCAAGAT AACAAATTGAT
#3961 GCTGACAACA AAAGCAAGAT AACAAATTGAT

>BS322 1199 to 2683 #793 ATTCATTTTC TTGAGAGGAA AATGCAACAT

```

>AF269087	#3991	ATTCATTTTC TTGAGAGGAA AATGCAACAT
	
	#3991	ATTCATTTTC TTGAGAGGAA AATGCAACAT
>BS322 1199 to 2683	#823	CATCTCCTAA AAGAGAAAAA TGAGGAGATA
>AF269087	#4021	CATCTCCTAA AAGAGAAAAA TGAGGAGATA
	
	#4021	CATCTCCTAA AAGAGAAAAA TGAGGAGATA
>BS322 1199 to 2683	#853	TTTAATTACA ATAACCATTT AAAAAACCGT
>AF269087	#4051	TTTAATTACA ATAACCATTT AAAAAACCGT
	
	#4051	TTTAATTACA ATAACCATTT AAAAAACCGT
>BS322 1199 to 2683	#883	ATATATCAAT ATGAAAAAGA GAAAGCAGAA
>AF269087	#4081	ATATATCAAT ATGAAAAAGA GAAAGCAGAA
	
	#4081	ATATATCAAT ATGAAAAAGA GAAAGCAGAA
>BS322 1199 to 2683	#913	ACAGAAAAC T CATGAGAGAC AAGCAGTAAG
>AF269087	#4111	ACAGAAAAC T CATGAGAGAC AAGCAGTAAG
	
	#4111	ACAGAAAAC T CATGAGAGAC AAGCAGTAAG
>BS322 1199 to 2683	#943	AAACTTCTTT TGGAGAAACA ACAGACCAGA
>AF269087	#4141	AAACTTCTTT TGGAGAAACA ACAGACCAGA
	
	#4141	AAACTTCTTT TGGAGAAACA ACAGACCAGA
>BS322 1199 to 2683	#973	TCTTTACTCA CAACTCATGC TAGGAGGCCA
>AF269087	#4171	TCTTTACTCA CAACTCATGC TAGGAGGCCA
	
	#4171	TCTTTACTCA CAACTCATGC TAGGAGGCCA

>BS322 1199 to 2683 #1003	GTCCTAGCAT CACCTTATGT TGAAAATCTT
>AF269087 #4201	GTCCTAGCAT CACCTTATGT TGAAAATCTT
#4201
	GTCCTAGCAT CACCTTATGT TGAAAATCTT
>BS322 1199 to 2683 #1033	ACCAATAGTC TGTGTCAACA GAATACTTAT
>AF269087 #4231	ACCAATAGTC TGTGTCAACA GAATACTTAT
#4231
	ACCAATAGTC TGTGTCAACA GAATACTTAT
>BS322 1199 to 2683 #1063	TTTAGAAGAA AAATTCATGA TTTCTTCCTG
>AF269087 #4261	TTTAGAAGAA AAATTCATGA TTTCTTCCTG
#4261
	TTTAGAAGAA AAATTCATGA TTTCTTCCTG
>BS322 1199 to 2683 #1093	AAGCCTACAG ACATAAAATA ACAGTGTGAA
>AF269087 #4291	AAGCCTACAG ACATAAAATA ACAGTGTGAA
#4291
	AAGCCTACAG ACATAAAATA ACAGTGTGAA
>BS322 1199 to 2683 #1123	GAATTACTTG TTCACGAA:T :C:TCGCTCT
>AF269087 #4321	GAATTACTTG TTCACGAATT GCATAAAGCT
#4321
	GAATTACTTG TTCACGAATT GCATMRMKCT
	* * * ****
>BS322 1199 to 2683 #1153	GCACTCCA:G CCTAGGCGCC TAGTGAAACC
>AF269087 #4351	GCACAGGATT CCCATCTACC CTGATGATGC
#4351
	GCACWSSATK CCYAKSYRCC YGWKRAWSC
	*** ** * ***** ** ****
>BS322 1199 to 2683 #1183	CTGTGTCA:A AAAGAAAA:A AACAAAAACA
>AF269087 #4381	AGCAGACATC ATTCAATCCA ACCAGAATCT
#4381
	MKSWGWCATM AWWSAAWMCA AMCARAACWCW
	***** * ** *** ** * * *

>BS322 1199 to 2683 #1213	AACT:TCCAA GAC:CTCGA: GTGGTTTTTG
>AF269087 #4411	CGCTCTGCAC TCCAGCCTAG GTGACAGAGT

#4411	MRCTCTSCAM KMCASYCKAG GTGRYWKWKK
	** * * * ** * * *
>BS322 1199 to 2683 #1243	GAGACCCTGT ATCACTTCAA ATAATGTGTT
>AF269087 #4441	GAGACTCCAC CTCGAAA

#4441	GAGACYCYRY MTCRSWWMAA ATAATGTGTT
	* *** * *****
>BS322 1199 to 2683 #1273	AAACAAGCAT CTTCATCTCA TTAAATAGAA

#4471	AAACAAGCAT CTTCATCTCA TTAAATAGAA
>BS322 1199 to 2683 #1303	ATGTTGAAAA ATTGCTTTTG GAATAATTGA

#4501	ATGTTGAAAA ATTGCTTTTG GAATAATTGA
>BS322 1199 to 2683 #1333	CTTATGGATA TTTCATCAAA TTTACAGTTG

#4531	CTTATGGATA TTTCATCAAA TTTACAGTTG
>BS322 1199 to 2683 #1363	GCTATGCTTT CTTATTGTGC ATACTATGAA

#4561	GCTATGCTTT CTTATTGTGC ATACTATGAA
>BS322 1199 to 2683 #1393	ATGTTTTTCT TCAAAAAGTG TTTATAAGTG

#4591	ATGTTTTTCT TCAAAAAGTG TTTATAAGTG
>BS322 1199 to 2683 #1423	GTAAGTTTAA GAATGGGGTT GACAGCATTA

#4621	GTAAGTTTAA GAATGGGGTT GACAGCATTA

>BS322 1199 to 2683 #1453

TCTTTTGTGG TTATTGATT AACATTTAC

#4651

.....
TCTTTTGTGG TTATTGATT AACATTTAC

>BS322 1199 to 2683 #1483

TAATTGTGCA TA

#4681

.....
TAATTGTGCA TA

EXHIBIT D

NYBR1list2.msfc{NY-BR-1}	1	mtkrkktinl	niqdaqkrt	lhvacvnghe	evvtflvdrk	cqldvldgeh	50
NYBR1list2.msfc{NYBR1sec25}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NYBR1sec24}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NY-BR-1}	51	rtplmkalqc	hqeacanili	dsgadinlvd	vygnmalhya	vyseilsvva	100
NYBR1list2.msfc{NYBR1sec25}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NYBR1sec24}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NY-BR-1}	101	klshgavie	vhnkasltpl	llsitkrseq	ivefllikna	nanavnykyc	150
NYBR1list2.msfc{NYBR1sec25}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NYBR1sec24}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NY-BR-1}	151	talmlavchg	sseivgmllq	qnvdfvaadi	cgvtaehyav	tcgfhhiheq	200
NYBR1list2.msfc{NYBR1sec25}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NYBR1sec24}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NY-BR-1}	201	imeyirklsk	nhqntnpegt	sagtpdeaap	laertpdae	slvektptdea	250
NYBR1list2.msfc{NYBR1sec25}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NYBR1sec24}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NY-BR-1}	251	aplvertptd	aeslvektptd	eaaslvvegts	dkiqclekat	sgkfegsaee	300
NYBR1list2.msfc{NYBR1sec25}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NYBR1sec24}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NY-BR-1}	301	tpreittpak	etsekftwpa	kgrprkiaawe	kkedtpreim	spaketsekf	350
NYBR1list2.msfc{NYBR1sec25}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NYBR1sec24}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NY-BR-1}	351	twaaakgrprk	iawekketpv	ktgcvarvts	nktkvlekgr	skmiacptke	400
NYBR1list2.msfc{NYBR1sec25}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NYBR1sec24}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NY-BR-1}	401	sstkasandq	rfpseskqee	deeyscdsrs	lfessakiqv	cipesiyqkv	450
NYBR1list2.msfc{NYBR1sec25}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NYBR1sec24}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NY-BR-1}	451	meinreveep	pkkpsafkpa	iemqnsvpnk	afelkneqtl	radpmfppes	500
NYBR1list2.msfc{NYBR1sec25}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NYBR1sec24}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NY-BR-1}	501	kqkdyeensw	dseslctetvs	qkdvcplpat	hqkeidking	kleespnkdg	550
NYBR1list2.msfc{NYBR1sec25}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NYBR1sec24}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NY-BR-1}	551	llkatcgmkv	siptkalelk	dmqtfkaepp	gkpsafepat	eMQKSVPNKA	600
NYBR1list2.msfc{NYBR1sec25}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NYBR1sec24}		~~~~~	~~~~~	~~~~~	~~~~~	~MQKSVPNKA	
NYBR1list2.msfc{NY-BR-1}	601	LELKNEQTwr	ADEILPSESK	QKDYEEsWD	tESLCETVSQ	KDVCLPKAAH	650
NYBR1list2.msfc{NYBR1sec25}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NYBR1sec24}		LELKNEQTlR	ADEILPSESK	QKDYEEsWD	sESLCETVSQ	KDVCLPKAAH	
NYBR1list2.msfc{NY-BR-1}	651	QKEIDKINGK	LEGSPVKDGL	LKANCgMKVS	IPTKALELMD	MQTFKAEPPE	700
NYBR1list2.msfc{NYBR1sec25}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
NYBR1list2.msfc{NYBR1sec24}		QKEIDKINGK	LEGSPVKDGL	LKANCgMKVS	IPTKALELMD	MQTFKAEPPE	
NYBR1list2.msfc{NY-BR-1}	701	KPSAFEPaIE	MQKSVPNKAL	ELKNEQTLRA	DEILPSESKQ	KDYEESSWDS	750
NYBR1list2.msfc{NYBR1sec25}		~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	

NYBR1list2.msf{NYBR1sec24}	KPSAFEPAlE	MQKSVPNKAL	ELKNEQTLRA	DEILPSESQK	KDYEESWDS
	751				800
NYBR1list2.msf{NY-BR-1}	ESLCETVSQK	DVCLPKATHQ	KEIDKINGKL	EESPDNDGFL	KAPCRMKVSI
NYBR1list2.msf{NYBR1sec25}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
NYBR1list2.msf{NYBR1sec24}	ESLCETVSQK	DVCLPKATHQ	KEIDKINGKL	EESPDNDGFL	KAPCRMKVSI
	801				850
NYBR1list2.msf{NY-BR-1}	PTKALELMDM	QTFKAEPPEK	PSAFEPAlEM	QKSVPNKALE	LKNEQTLRAD
NYBR1list2.msf{NYBR1sec25}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
NYBR1list2.msf{NYBR1sec24}	PTKALELMDM	QTFKAEPPEK	PSAFEPAlEM	QKSVPNKALE	LKNEQTLRAD
	851				900
NYBR1list2.msf{NY-BR-1}	QMFPSESKQK	kVEENSWDSE	SLRETVSQKD	VCVPKATHQK	EMDKISGKLE
NYBR1list2.msf{NYBR1sec25}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
NYBR1list2.msf{NYBR1sec24}	QMFPSESKQK	nVEENSWDSE	SLRETVSQKD	VCVPKATHQK	EMDKISGKLE
	901				950
NYBR1list2.msf{NY-BR-1}	DSTLSKILD	TvHSCERARE	LQKDHCEQrT	GKMEQMKKKF	CVLKKKLSEA
NYBR1list2.msf{NYBR1sec25}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
NYBR1list2.msf{NYBR1sec24}	DSTLSKILD	TiHSCERARE	LQKDHCEQcT	GKMEQMKKKF	CVLKKKLSEA
	951				1000
NYBR1list2.msf{NY-BR-1}	KEIKSQLENQ	KVKWEQELCS	VRltlnqeee	krrnadIlne	kireelgrie
NYBR1list2.msf{NYBR1sec25}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
NYBR1list2.msf{NYBR1sec24}	KEIKSQLENQ	KVKWEQELCS	VRfltImkmk	iisymkIac~	~~~~~
	1001				1050
NYBR1list2.msf{NY-BR-1}	eqhrkelevk	qqlqalriq	dielksvesn	lnqVSHTHEN	ENYLLHENCm
NYBR1list2.msf{NYBR1sec25}	~~~~~	~~~~~	~~~~mgtral	qceVSHTHEN	ENYLLHENCm
NYBR1list2.msf{NYBR1sec24}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
	1051				1100
NYBR1list2.msf{NY-BR-1}	LKKEIAMLKL	EIATLKHQYQ	EKENKYFEDI	KILKEKNAEL	QMTLKLKEES
NYBR1list2.msf{NYBR1sec25}	LKKEIAMLKL	EIATLKHQYQ	EKENKYFEDI	KILKEKNAEL	QMTLKLKEES
NYBR1list2.msf{NYBR1sec24}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
	1101				1150
NYBR1list2.msf{NY-BR-1}	LTKRASQYSG	QLKVLIAENT	MLTSKLKEKQ	DKEILEAEIE	SHHPRLASAV
NYBR1list2.msf{NYBR1sec25}	LTKRASQYSG	QLKVLIAENT	MLTSKLKEKQ	DKEILEAEIE	SHHPRLASAV
NYBR1list2.msf{NYBR1sec24}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
	1151				1200
NYBR1list2.msf{NY-BR-1}	QDHDQIVTSR	KSQEPAFHIA	GDACLQRKMn	VDVSSTIYNN	EVLHQPLSEA
NYBR1list2.msf{NYBR1sec25}	QDHDQIVTSR	KSQEPAFHIA	GDACLQRKMn	VDVSSTIYNN	EVLHQPLSEA
NYBR1list2.msf{NYBR1sec24}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
	1201				1250
NYBR1list2.msf{NY-BR-1}	QRKSKSLKIN	LNYAGDALRE	NTLVSEHAQR	DQRETQCQMK	EAEHMYQNEQ
NYBR1list2.msf{NYBR1sec25}	QRKSKSLKIN	LNYAGDALRE	NTLVSEHAQR	DQRETQCQMK	EAEHMYQNEQ
NYBR1list2.msf{NYBR1sec24}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
	1251				1300
NYBR1list2.msf{NY-BR-1}	DNVNKHTEQQ	ESLDQKLFQL	QSKNMWLQQQ	LVHAHKKADN	KSKITIDIHF
NYBR1list2.msf{NYBR1sec25}	DNVNKHTEQQ	ESLDQKLFQL	QSKNMWLQQQ	LVHAHKKADN	KSKITIDIHF
NYBR1list2.msf{NYBR1sec24}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
	1301				1341
NYBR1list2.msf{NY-BR-1}	LERKMQHLL	KEKNEEIFNY	NNHLKNRIYQ	YEKEKAETEN	S
NYBR1list2.msf{NYBR1sec25}	LERKMQHLL	KEKNEEIFNY	NNHLKNRIYQ	YEKEKAETEN	S
NYBR1list2.msf{NYBR1sec24}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~